EQ Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Equillium Inc (EQ) is not a strong buy at this moment for a beginner investor with a long-term strategy and $50,000-$100,000 to invest. The company's financial performance is weak, with significant revenue and income declines. Insider selling has increased, and there are no strong proprietary trading signals or recent congress trading data to support a buy decision. While analysts have issued buy ratings with optimistic price targets, the company's preclinical status and lack of immediate catalysts make it a risky investment at this time.
The technical indicators are mixed. The MACD is negatively expanding, indicating bearish momentum. RSI is neutral at 50.09, and moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock is trading below its pivot level (2.248), with key support at 1.943 and resistance at 2.553.
Analysts have issued buy ratings with price targets of $5 and $12, citing potential in the ulcerative colitis market. The company completed a $35 million financing round to support operations through 2029.
Insiders are selling heavily, with a 102.15% increase in selling activity over the last month. The company's financials show a 100% drop in revenue and a 34.85% decline in net income YoY. The stock has a 60% chance to decline by 10.4% over the next month.
In Q4 2025, Equillium reported a 100% YoY revenue decline, a 34.85% YoY drop in net income, and a 75% YoY decline in EPS. Gross margin also dropped to 0%. Despite beating EPS expectations by $0.02, the overall financial performance is weak.
Roth Capital and Stifel have initiated buy ratings with price targets of $12 and $5, respectively. Analysts are optimistic about the company's EQ504 drug entering Phase 1 trials and its potential in the ulcerative colitis market.
